Rockville, Maryland – Samsung Biologics has officially completed its $353 million acquisition of GSK’s manufacturing facility in Rockville, Maryland, marking a significant expansion of the South Korean firm’s presence in the United States and bolstering the region’s growing biopharmaceutical sector. The deal, first announced in December 2025, establishes Samsung Biologics’ first US-based manufacturing site and adds 60,000 liters of capacity for both clinical and commercial biologics production.
The acquisition isn’t simply about increased capacity; it’s a strategic move for Samsung Biologics to diversify its manufacturing network and better serve a growing global client base. The Rockville facility brings two cGMP (Current Good Manufacturing Practice) plants into the Samsung Biologics portfolio, increasing the company’s total drug substance production capacity to 845,000 liters. This expansion comes as demand for biologics – complex medicines derived from living organisms – continues to rise.
A Smooth Transition for Existing Production
A key component of the agreement ensures continuity for existing pharmaceutical products. Samsung Biologics will continue to manufacture products previously made at the site for GSK under existing contractual obligations. This minimizes disruption for patients and partners reliant on those medications. Simultaneously, the company intends to actively seek new contract manufacturing projects, leveraging the facility’s capabilities to support a wider range of pharmaceutical clients.
Investment and Expansion Plans for the Rockville Site
The acquisition isn’t a static event. Samsung Biologics has publicly committed to further investment in the Rockville plant. Plans are underway to expand capacity and implement technology upgrades, though specific details regarding those upgrades are still being assessed. Company representatives have indicated they are currently evaluating the facility’s existing capabilities and equipment to determine the optimal path for future development. This phased approach allows for a targeted and efficient allocation of resources.
Maryland Welcomes New Investment and Jobs
The arrival of Samsung Biologics has been met with enthusiasm from Maryland officials. Governor Wes Moore attended a ribbon-cutting event at the Rockville site, alongside Samsung Biologics executives and local leaders, signifying the state’s commitment to fostering a thriving life sciences industry. Maryland.gov highlights the economic benefits of the acquisition.
Crucially, the deal preserves more than 500 jobs in Montgomery County, Maryland. Beyond job retention, the acquisition positions the state for potential future investment from Samsung Biologics, further solidifying Maryland’s role as a hub for biopharmaceutical innovation. The state’s robust biopharmaceutical sector, coupled with its proximity to federal research institutions like the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), were cited by Samsung Biologics as key factors in selecting Rockville for its US expansion.
CEO Rim Highlights Strategic Importance
Samsung Biologics President and CEO John Rim emphasized the strategic importance of the acquisition. “This represents a meaningful step in expanding our US manufacturing footprint,” Rim said in a statement. “The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family.”
Governor Moore echoed this sentiment, noting the collaborative effort that led to the deal. “During our international trade mission last year, we met with the Samsung Biologics team in Seoul to discuss the economic momentum in Maryland,” Moore stated. “Today’s ribbon cutting is the realization of that meeting and our state’s momentum.”
Maryland’s Growing Life Sciences Ecosystem
The Samsung Biologics acquisition is part of a broader trend of investment in Maryland’s life sciences sector. State officials point to other recent investments by international firms as evidence of the region’s growing attractiveness. Currently, Maryland is home to nearly 5,000 life sciences businesses, employing over 54,000 workers. The state’s commitment to supporting research and development, coupled with a skilled workforce, is driving continued growth in the industry.
Samsung Biologics’ entry into the US market is expected to not only bolster regional economic growth but also provide expanded manufacturing options for pharmaceutical companies seeking reliable and high-quality contract manufacturing services. The Rockville facility is poised to play a critical role in the development and production of innovative medicines for years to come.
Looking ahead, Samsung Biologics will focus on integrating the Rockville facility into its global network and executing its planned capacity expansions. The company is expected to provide further details on its investment plans in the coming months. Readers interested in updates on Samsung Biologics’ US operations can visit the company’s official website.
Do you have thoughts on this acquisition? Share your comments below.
Related reading
